(preramble.... the short thesis is that the company will need funding before eravacycline can complete testing, that they'll need to dilute at a low share price)
Market cap is $148m
Cash, 12/31, $206m
Book, 12/31, $204m
Assets in development:
eravacycline, phase III development for intravenous, phase I for oral, drug-resistant Gram-negatives;
TP-271, phase I development funded by NIH, community-acquired bacterial pneumonia;
TP-6076, scheduled phase I by 3Q16, carbapenem-resistant K. pneumoniae, A. baumannii and E. coli.
Hoping that we'll hear something about 271 or 6076 at ICAAC, 16-20 June.... asmmicrobe.org |
